Update on systemic treatment for newly diagnosed inflammatory breast cancer.

Antineoplastic Agents / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Chemotherapy, Adjuvant / methods Clinical Trials as Topic Female Humans Immunotherapy / methods Inflammatory Breast Neoplasms / diagnosis Molecular Targeted Therapy / methods Neoadjuvant Therapy / methods Receptor, ErbB-2 / metabolism Survival Rate Trastuzumab / therapeutic use Treatment Outcome
Chemotherapy Immunotherapy Inflammatory breast cancer Systemic therapy Targeted therapy

Journal

Journal of advanced research
ISSN: 2090-1224
Titre abrégé: J Adv Res
Pays: Egypt
ID NLM: 101546952

Informations de publication

Date de publication:
03 2021
Historique:
received: 16 05 2020
revised: 31 07 2020
accepted: 21 08 2020
entrez: 12 4 2021
pubmed: 13 4 2021
medline: 25 9 2021
Statut: epublish

Résumé

Inflammatory breast cancer (IBC) is a rare and aggressive disease, accounting for 2-4% of new cases of breast cancer. Owing to its aggressive nature, IBC represent approximately 8-10% of breast cancer deaths. Management of IBC requires a multidisciplinary team for decision-making involving a composite of systemic treatment, surgery, and radiation, or "Trimodality Treatment." Because of the rarity of the disease, systemic therapy of IBC traditionally has been extrapolated from non-IBC clinical trials. The purpose of this review is to provide an overview of the development of systemic treatment of IBC from the past to the present by focusing on IBC clinical trials, including chemotherapy and targeted therapies. We discuss their effects on pathologic complete response (pCR) and survival outcomes, the predictive markers, and the adverse events of these therapies. Further, we summarized the current standard treatment stratified by molecular subtypes based on clinical data. Finally, we discuss the future trend of systemic therapy, including immunotherapy and ongoing IBC clinical trials.

Sections du résumé

Background
Inflammatory breast cancer (IBC) is a rare and aggressive disease, accounting for 2-4% of new cases of breast cancer. Owing to its aggressive nature, IBC represent approximately 8-10% of breast cancer deaths. Management of IBC requires a multidisciplinary team for decision-making involving a composite of systemic treatment, surgery, and radiation, or "Trimodality Treatment." Because of the rarity of the disease, systemic therapy of IBC traditionally has been extrapolated from non-IBC clinical trials.
Aim of Review
The purpose of this review is to provide an overview of the development of systemic treatment of IBC from the past to the present by focusing on IBC clinical trials, including chemotherapy and targeted therapies.
Key Scientific Concepts of Review
We discuss their effects on pathologic complete response (pCR) and survival outcomes, the predictive markers, and the adverse events of these therapies. Further, we summarized the current standard treatment stratified by molecular subtypes based on clinical data. Finally, we discuss the future trend of systemic therapy, including immunotherapy and ongoing IBC clinical trials.

Identifiants

DOI: 10.1016/j.jare.2020.08.014 PMID: 33842000 PMC: PMC8020152
pubmed: 33842000
doi: 10.1016/j.jare.2020.08.014
pii: S2090-1232(20)30200-9
pmc: PMC8020152
doi:

Substances chimiques

Antineoplastic Agents 0
Receptor, ErbB-2 EC 2.7.10.1
Trastuzumab P188ANX8CK

Types de publication

Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Informations de copyright

© 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University.

Déclaration de conflit d'intérêts

Naoto T. Ueno has a research agreement with Amgen, Celgene and PUMA Oncology. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200-8
pubmed: 12654428
Clin Breast Cancer. 2022 Jan;22(1):32-42
pubmed: 34158245
Cancer. 2008 May 1;112(9):1905-11
pubmed: 18300243
Lancet Oncol. 2018 Jan;19(1):115-126
pubmed: 29175149
Bone Marrow Transplant. 2001 May;27(9):989-98
pubmed: 11436111
JAMA. 1995 Feb 15;273(7):542-7
pubmed: 7837388
JAMA Oncol. 2018 Sep 1;4(9):1207-1213
pubmed: 29879283
Ann Oncol. 2015 Aug;26(8):1692-7
pubmed: 25943350
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Oncotarget. 2015 May 30;6(15):13506-19
pubmed: 25940795
Breast Cancer Res Treat. 2013 Jan;137(2):471-82
pubmed: 23239151
Oncotarget. 2017 Jul 25;8(30):49370-49379
pubmed: 28472761
Oncogene. 2009 Feb 12;28(6):803-14
pubmed: 19060928
J Clin Oncol. 2018 May 1;36(13):1308-1316
pubmed: 29543566
Lancet Oncol. 2013 Sep;14(10):933-42
pubmed: 23932548
J Cancer. 2020 Jan 1;11(2):292-300
pubmed: 31897225
Clin Breast Cancer. 2018 Aug;18(4):328-335
pubmed: 29486983
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
PeerJ. 2019 Sep 16;7:e7659
pubmed: 31576238
Lancet Oncol. 2012 Feb;13(2):135-44
pubmed: 22257523
Br J Radiol. 2011 Jul;84(1003):612-20
pubmed: 21081579
J Clin Oncol. 2014 Jul 1;32(19):2018-24
pubmed: 24888808
Bone Marrow Transplant. 1998 Feb;21(3):249-54
pubmed: 9489647
Ann Oncol. 2007 Jun;18(6):1021-9
pubmed: 17351259
Ann Surg Oncol. 2014 Apr;21(4):1267-70
pubmed: 24366421
Am J Clin Pathol. 2018 Feb 17;149(3):253-261
pubmed: 29425258
J Clin Oncol. 2004 Oct 15;22(20):4067-74
pubmed: 15483018
Cancer. 2018 Jun 1;124(11):2299-2305
pubmed: 29579338
Clin Cancer Res. 2015 Mar 15;21(6):1298-304
pubmed: 25538259
Breast Cancer Res. 2019 Feb 18;21(1):28
pubmed: 30777104
Future Oncol. 2019 Feb;15(5):507-516
pubmed: 30378451
Anticancer Res. 2012 Aug;32(8):3539-45
pubmed: 22843943
N Engl J Med. 2003 Nov 6;349(19):1793-802
pubmed: 14551341
Breast Cancer Res Treat. 2017 Apr;162(2):365-374
pubmed: 28138891
Clin Breast Cancer. 2016 Jun;16(3):212-6
pubmed: 26988771
Br J Cancer. 1999 Oct;81(3):449-56
pubmed: 10507769
Cancer. 2011 May 1;117(9):1819-26
pubmed: 21509759
Ann Oncol. 2013 Sep;24(9):2278-84
pubmed: 23704196
Eur J Cancer. 2018 Jan;89:27-35
pubmed: 29223479
Nat Rev Cancer. 2009 Jul;9(7):463-75
pubmed: 19536107
Expert Rev Anticancer Ther. 2017 Jul;17(7):593-606
pubmed: 28506194
Expert Opin Investig Drugs. 2017 Apr;26(4):463-479
pubmed: 28271910
Ann Oncol. 2019 Oct 1;30(10):1674
pubmed: 31236598
Lancet Oncol. 2016 May;17(5):600-11
pubmed: 27032301
Breast. 2004 Apr;13(2):97-103
pubmed: 15019688
Ann Oncol. 2015 Feb;26(2):313-20
pubmed: 25403582
Ann Oncol. 2014 Feb;25(2):358-65
pubmed: 24299959
Ann Oncol. 2011 Mar;22(3):515-523
pubmed: 20603440
J Clin Oncol. 2015 Jan 1;33(1):13-21
pubmed: 25092775
Ann Oncol. 2014 Feb;25(2):384-91
pubmed: 24351399
Ann Oncol. 2017 Jan 1;28(1):103-109
pubmed: 28177480
Clin Breast Cancer. 2015 Feb;15(1):1-7
pubmed: 25034439
J Cell Physiol. 2016 Nov;231(11):2541-7
pubmed: 27187274
Lancet Oncol. 2014 Jun;15(7):747-56
pubmed: 24794243
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Cancer. 2001 Oct 1;92(7):1775-82
pubmed: 11745249
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Breast Cancer Res. 2009;11(1):R9
pubmed: 19228416
Lancet Oncol. 2016 Jun;17(6):791-800
pubmed: 27179402
Breast Cancer Res Treat. 2012 Aug;134(3):1257-68
pubmed: 22733221
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
J Clin Oncol. 2013 May 10;31(14):1719-25
pubmed: 23569311
N Engl J Med. 2016 Jul 21;375(3):209-19
pubmed: 27264120
Clin Breast Cancer. 2010 Dec 1;10(6):483-8
pubmed: 21147693
J Clin Oncol. 2011 Mar 10;29(8):1014-21
pubmed: 21220618
Breast Cancer Res Treat. 2015 Jul;152(2):407-16
pubmed: 26017070
Clin Breast Cancer. 2004 Feb;4(6):415-9
pubmed: 15023242
Bone Marrow Transplant. 1999 Nov;24(9):981-7
pubmed: 10556957
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Breast Cancer Res Treat. 2020 Feb;180(1):207-217
pubmed: 31960171
J Clin Oncol. 2010 Jul 10;28(20):3248-55
pubmed: 20530274
N Engl J Med. 2012 Jan 12;366(2):109-19
pubmed: 22149875
J Natl Cancer Inst. 2005 Jul 6;97(13):966-75
pubmed: 15998949
J Cancer. 2017 Mar 25;8(6):1009-1017
pubmed: 28529613
Lancet. 2012 Feb 18;379(9816):633-40
pubmed: 22257673
Int J Cancer. 1995 Aug 9;62(4):382-5
pubmed: 7635562
Breast Cancer Res Treat. 2013 Feb;137(3):755-66
pubmed: 23283526
J Clin Oncol. 2008 Mar 1;26(7):1066-72
pubmed: 18212337
J Clin Oncol. 1997 May;15(5):1870-9
pubmed: 9164197
Breast Cancer Res Treat. 2018 Sep;171(2):273-282
pubmed: 29858752
PLoS Med. 2016 Dec 6;13(12):e1002136
pubmed: 27923043
Cancer Chemother Pharmacol. 1997;40(4):321-9
pubmed: 9225950
Breast Cancer Res Treat. 2019 Jul;176(1):217-226
pubmed: 30972613
Cancer Causes Control. 2014 Aug;25(8):959-68
pubmed: 24839049
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Ann Surg Oncol. 2018 Jul;25(7):1783-1785
pubmed: 29671136
J Cancer. 2018 Apr 6;9(8):1437-1447
pubmed: 29721054
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Breast Cancer Res. 2014 Mar 05;16(2):209
pubmed: 24887180
Breast Cancer Res. 2019 Oct 17;21(1):113
pubmed: 31623649
Ann Oncol. 2018 Mar 1;29(3):646-653
pubmed: 29253081
Cancer Chemother Pharmacol. 1990;27(2):94-100
pubmed: 2249339
Lancet Oncol. 2014 May;15(6):640-7
pubmed: 24657003
Clin Breast Cancer. 2004 Dec;5(5):358-63
pubmed: 15585073
J Clin Oncol. 2004 May 15;22(10):1839-48
pubmed: 15143076
N Engl J Med. 2018 Jul 12;379(2):122-137
pubmed: 29863451

Auteurs

Sudpreeda Chainitikun (S)

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Sadia Saleem (S)

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Bora Lim (B)

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Vicente Valero (V)

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Naoto T Ueno (NT)

Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Update on systemic treatment for newly...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Update on systemic treatment for newly...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitement médicamenteux adjuvant › Update on systemic treatment for newly...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Update on systemic treatment for newly...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Update on systemic treatment for newly...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Update on systemic treatment for newly...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Cancers du sein inflammatoires › Update on systemic treatment for newly...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › Update on systemic treatment for newly...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Traitement néoadjuvant › Update on systemic treatment for newly...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › Update on systemic treatment for newly...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Update on systemic treatment for newly...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Trastuzumab › Update on systemic treatment for newly...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Update on systemic treatment for newly...